Investor

Alta Life Sciences

altals.com ↗ ·Barcelona ·Multi stage ·Fully deployed

Alta Life Sciences (rebranded Aliath Bioventures) was a Barcelona-headquartered multistage venture capital platform, part of the AltamarCAM group, investing from seed through commercial growth in biotechnology, medical devices, diagnostics, genomics and digital health. In October 2025 its investment team and funds were fully integrated into Asabys Partners; it no longer operates independently.

Portfolio

Team

AUM

n/a

Rounds

SectorsBiotechnology, Medical devices, Diagnostics, Genomics, Digital health VC MapSeries B

Profile updated 18 Jul 2026

Team

Partners 5 Investment Team 1 Others 0

Guy P. Nohra

Managing General Partner (Alta Life Sciences)

Joana Correia

Senior Investment Analyst (Aliath Bioventures) — now at Asabys Partners

José María Fernández

Founding Partner (Aliath Bioventures) — now Partner at Asabys Partners

—

Miguel Valls

Founding Partner and CEO (Alta Life Sciences)

Montserrat Vendrell

Partner (Alta Life Sciences/Aliath) — now Partner at Asabys Partners

Portfolio companies 9

Accure Therapeutics

accuretherapeutics.com

Company Series A Barcelona

ARTHEx Biotech

arthexbiotech.com

Company Series B Valencia

deepull

deepull.com

Company Series C Barcelona

Inbiomotion

inbiomotion.com

Company Series A Barcelona

INBRAIN Neuroelectronics

inbrain-neuroelectronics.com

Company Series B Barcelona

Mediktor

mediktor.com

Company Series B Barcelona

Ona Therapeutics

ona-therapeutics.com

Company Series B Barcelona

Peptomyc

peptomyc.com

Company Series C Barcelona

Sanifit

sanifit.com

Company Series D Palma de Mallorca

Funding rounds 10

Ona Therapeutics · Series B · €74.2M

IRB Barcelona spin-out closed an oversubscribed €74.2M Series B co-led by Columbus and Mérieux to take its first-in-class antibody-drug conj…

2026-06-04

DeepUll · Series B · €17M

Barcelona Science Park-based DeepUll, which develops culture-free molecular diagnostics for early sepsis detection, announced that Sabadell …

2023-03-01

DeepUll · Series B · €13M

DeepUll develops culture-free diagnostics for early sepsis detection. It raised a €13M Series B led by Innvierte (CDTI) together with an und…

2022-10-20

Peptomyc · Other · €8.6M

Peptomyc, a VHIO/ICREA spin-off developing the MYC-inhibitor cancer drug OMO-103, secured €8.6M from its existing shareholders via a convert…

2022-01-20

Mediktor · Series B · €11M

Mediktor (legal entity Teckel Medical) raised an €11M Series B led by Swiss healthtech growth investor MTIP through its Fund II, with existi…

2021-10-04

Inbiomotion · Other

Inbiomotion, an IRB Barcelona spin-off behind the MAF biomarker test for early breast cancer, closed an oversubscribed round of undisclosed …

2021-01-21

Peptomyc · Series A · €11.4M

Peptomyc is a spin-off of VHIO and ICREA developing Omomyc-based peptide therapies against MYC-driven cancers. It closed an €11.4M equity ro…

2020-12-16

DeepUll · Series A · €3.5M

DeepUll is based at the Barcelona Science Park and is developing a rapid diagnostic system for early-stage sepsis. It closed a €3.5M Series …

2020-07-07

Accure Therapeutics · Series A · €7.6M

Accure Therapeutics, formed by merging Iproteos and Bionure, launched with a €7.6M Series A led by Alta Life Sciences and backed by CDTI. It…

2020-05-26

Mediktor · Series A · €3M

Mediktor closed a €3M Series A led by Barcelona-based Alta Life Sciences through its Alta Life Sciences Spain I FCR fund, with Dutch investo…

2018-10-02

News & media 6

Published	Article
2026-06-04	Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development ↗ GlobeNewswire
2025-10-02	Asabys Partners Integrates Aliath Bioventures Life Sciences Investment Platform in Strategic Move with AltamarCAM ↗ PR Newswire
2025-04-29	deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection ↗ GlobeNewswire
2025-04-07	Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson's disease to clinical trials ↗ Accure Therapeutics (press release)
2024-10-29	INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology ↗ Business Wire
2023-11-16	Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business ↗ Aliath Bioventures (press release)